Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

Completed · Phase 4 · Has a placebo group

Conditions studied: Allergic Rhinitis

In brief

Dymista, a combined product containing the antihistamine azelastine and the intranasal steroid fluticasone, provides superior clinical efficacy to both fluticasone propionate and azelastine hydrochloride in the treatment of seasonal allergic rhinitis. The superiority of efficacy not only occurs at the initiation of treatment, but persists for its duration. The mechanism underlying the superior efficacy of Dymista is not known. This trial focuses on examining the effects of Dymista on the dynamics of the allergic response in man using nasal provocation with antigen. The investigators will study the relationship between symptoms, physiology, cells and mediators.

Key facts

Study ID

NCT02402465

Run by

University of Chicago

People needed

22

Starts

2015-02-01

Expected to finish

2020-02-01

Last updated by the study team

2024-10-17

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males and females between 18 and 55 years of age.
• History of grass and/or ragweed allergic rhinitis.
• Positive skin test to grass and/or ragweed antigen.
• Positive response to screening nasal challenge.
• Off all anti-allergic medications for a minimum of 2 weeks.

You may not qualify if…

• Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
• Pregnant or lactating women.
• Upper respiratory infection within 14 days of study start.

Where it is running

• The University of Chicago Medicine — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.